Tango Therapeutics, Inc. (TNGX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions.
Is Tango Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Tango Therapeutics, Inc. (TNGX) trades at $22.72 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Tango Therapeutics, Inc.
Market cap $4B · 52 weeks $8 – $33 (31 % below the high) · P/E no earnings · Dividend none · Next earnings November 3, 2026 · expected EPS $-0.35 · Closing price, Oct 30 · accounts published Aug 10.
- Valuation: P/Sales 26.1× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 5.0 %, fails.
- Market cap / Cash 7.7×, fails.
- Cash Runway 30 meses, passes.
- Total Debt 0.1×, passes.
- Annual cash burn $1.20, info.
Against its peers (reference peers) — Tango Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -12.9 %; $3.8B. Nurix Therapeutics, Inc. (P/E 11.6×; EV/EBITDA 7.0×; ROIC 25.9 %; $2.9B), Arcutis Biotherapeutics, Inc. (P/E 154×; EV/EBITDA 94.7×; ROIC 9.9 %; $4.0B), Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B).
Profitability
| Return on Equity | -25.74% |
| Return on Invested Capital | -12.90% |
| Return on Assets | -11.52% |
| Gross Margin | 98.25% |
| Operating Margin | -253.38% |
| Net Margin | -229.92% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 50.82 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 9.88 |
Price Performance
| 1 month | -2.24% |
| 3 months | -16.50% |
| Year-to-date | +156.43% |
| 1 year | +180.15% |
| 3 years | +169.51% |
| 5 years | +76.40% |
Related companies: RVMD · ERAS · IDYA · RLAY · NRIX
Explore sector: Healthcare · Biotechnology
More sections of TNGX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks